Section Arrow
Quote
TECX.NASDAQ
- Tectonic Therapeutic Inc.
Quotes are at least 15-min delayed:2026/01/09 07:34 EST
Pre Market
Last
 --
-- (--)
Bid
20.3
Ask
23
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 21.46
-0.28 (-1.29%)
Day High 
21.53 
Prev. Close
21.74 
1-M High
22 
Volume 
193.91K 
Bid
20.3
Ask
23
Day Low
20.845 
Open
21.26 
1-M Low
17.79 
Market Cap 
406.89M 
Currency 美元 
P/E 4.67 
%Yield -- 
10-SMA 20.96 
20-SMA 20.15 
50-SMA 19.46 
52-W High 61.07 
52-W Low 13.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.69/-4.36
Enterprise Value
407.41M
Balance Sheet
Book Value Per Share
14.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1033-0.0223-17.75%-- 
Pre Market 0.1005 -0.0028 -2.71%
ACRVAcrivon Therapeutics1.93-1.02-34.58%-- 
Pre Market 1.89 -0.04 -2.07%
VTYXVentyx Biosciences13.84+0.11+0.80%-- 
Pre Market 13.81 -0.03 -0.22%
MLTXMoonLake Immunotherapeutics14.34+3.05+27.02%-- 
Pre Market 15.2 +0.86 +6.00%
CRMDCorMedix7.51-3.66-32.77%5.05PE
Pre Market 7.53 +0.02 +0.27%
Industry overview quotes are at least 15 minutes delayed
Business Description
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.